Business
Notice of Business Update & Investor Presentation
Notice of Business Update & Investor Presentation.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n\n \nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or \"the Company\")\n \nNotice of Business Update and Investor Presentation\n \nNewcastle, UK - 15 July 2024 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, confirms that it will announce an update on the business on Monday 29 July 2024 and the management team will make a presentation via the Investor Meet Company platform at 10am on that day.\n \nQuestions can be submitted pre-event via the Investor Meet Company dashboard up to the day before the meeting or at any time during the live presentation. Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited.\n \nInvestors can sign up to Investor Meet Company for free at this link.\n \n-Ends-\n \n \nFor more information please contact:\n \n\n\n\n\nSkinBioTherapeutics plc\nStuart J. Ashman, CEO\nManprit Randhawa, CFO\n \n\n\nTel: +44 (0) 191 495 7325\n \n\n\n\n\nCavendish Capital Markets Limited\n(Nominated Adviser & Broker)\nGiles Balleny, Dan Hodkinson (Corporate Finance)\nCharlie Combe (Broking)\nDale Bellis, Tamar Cranford-Smith (Sales)\n \n\n\nTel: +44 (0) 20 7220 0500\n \n\n\n\n\nInstinctif Partners (Media)\nMelanie Toyne-Sewell / Jack Kincade\n \n\n\nTel: +44 (0) 20 7457 2020\[email protected]\n \n\n\n\n\nNotes to Editors\nAbout SkinBioTherapeutics plc\nSkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.\nThe Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.\nThe Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.\n \n \n\n","length":6518,"tagName":"div"}]